Long Term Follow-up After Primary or Revision Shoulder Arthroplasty With a Patient- Specific Glenius Implant
Launched by MATERIALISE · Jan 15, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The Glenius glenoid implant is a solution for patients who need a reversed glenoid reconstruction (primary or revision) because of a severely damaged glenoid associated with severe bone loss. In these cases, standard reconstruction of the glenoid is not possible because of the lack of body support of the glenoid rim or columns.
The Glenius implant is custom-made prothesis: during pre-operative planning, the implant is designed based on a detailed 3D CT analysis of the defect with special reference to bone quality and the anatomy of the bone deficient glenoid. Optimized screw fixation traje...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients having primary or revision shoulder joint replacement with severe glenoid bone defects
- • Patient is 18 years of age or older
- • Patient can follow the Glenius system procedure that is standard of care
- • Patient is willing to cooperate in the required post-operative therapy
- • Patient has participated in the informed consent process and has signed the EC approved informed consent form
- Exclusion Criteria:
- • Pregnant patients
- • Skeletally immature patients
- • Prisoners
About Materialise
Materialise is a leading global provider of 3D printing solutions and medical software, dedicated to advancing the field of personalized healthcare through innovative technologies. With a strong emphasis on research and development, Materialise collaborates with healthcare professionals and institutions to enhance patient outcomes by offering cutting-edge tools for surgical planning, medical device development, and custom implants. Their commitment to quality and precision in the clinical trial process ensures that new therapeutic approaches are rigorously evaluated, paving the way for breakthroughs in patient care and treatment efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Herentals, , Belgium
Leuven, , Belgium
Leuven, , Belgium
Delft, , Netherlands
Nijmegen, , Netherlands
Leuven, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials